Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen manufacturing warning letter

Executive Summary

Amgen resolves manufacturing problems surrounding Kineret (anakinra) July 7, company says. FDA May 9 1warning letter cited Amgen's Boulder, Colo. manufacturing facility; infractions included lack of thorough investigation of filtered purified bulk; construction and expansion of support systems without adequate change control; failure to notify FDA of changes to production process; and exporting product not intended for export...
Advertisement

Related Content

Kineret GMP Warning Letter Prompts Changes To Internal Amgen Inspections
Advertisement
UsernamePublicRestriction

Register

PS042411

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel